DTC
ALNY icon

Deep Track Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Deep Track Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-499,900
Closed -$72.9M – 67
2022
Q2 		$72.9M Buy
+499,900
New +$70.9M 4.79% 5

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deep Track Capital's ALNY Position: Q2 2026 in Review

Deep Track Capital opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 825,000 shares worth $248M. The stake represents 3.61% of the portfolio and ranks #5 among its holdings. This is a return to the name: Deep Track Capital previously reported a position in ALNY as recently as Q2 2024.

Deep Track Capital first reported a position in ALNY in Q1 2022 and has held it in 4 quarters since. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Deep Track Capital held 825,000 shares of Alnylam Pharmaceuticals worth $248M as of Q2 2026.
  • Alnylam Pharmaceuticals was a new Deep Track Capital position in Q2 2026.
  • Alnylam Pharmaceuticals made up 3.61% of Deep Track Capital's portfolio in Q2 2026, its #5 holding.
  • Deep Track Capital first reported a position in Alnylam Pharmaceuticals in Q1 2022 and has held it in 4 quarters since.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Deep Track Capital's 13F filing for Q2 2026, filed 14 Aug 2026.